Singular Health Group Ltd (SHG)

Snapshot

SHG's Principal Activity is the sale and development of medical imaging and visualisation software and technology.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Mr Andrew Ian Just	Non-Executive Director	Jan 2021	Mr Andrew Ian Just Non-Executive Director Mr Just was employed by Roche Pharmaceuticals as a Health Economist. He built economic models for inclusion of Roche products on the Australian Medical Benefits Scheme and then in GE Healthcare where he was appointed General Manager of Services for Australia and New Zealand. He has since gained over 25 years of senior executive experience in the healthcare industry at Fortune 500 and ASX listed companies including Stryker, Cochlear, GE Healthcare, Radiometer, Roche, and Novartis. Andrew has prior ASX experience having previously been the Chief Executive Officer and Managing Director of ASX listed company Paragon Care Limited (ASX:PGC). He is also Chairman of Risk Committee of SHG.
Mr Howard Andrew Digby	Non-Executive Chairman,Non-Executive Director	Jan 2021	Mr Howard Andrew Digby Non-Executive Chairman,Non-Executive Director Mr Digby began his career at IBM and has spent over 25 years managing technology-related businesses in the Asia Pacific region, of which 11 years were spent in Hong Kong. Prior to returning to Perth, Howard was with The Economist Group as Regional Managing Director. He has also held senior regional management roles at Adobe and Gartner. Currently a Non-Executive Director of 4DS Memory (ASX:4DS), Elsight (ASX:ELS), Cirralto (ASX:CRO), Vortiv (ASX:VRO) and previously a Non-Executive Director of ImeHXS (ASX:IME), Howard has ASX and corporate governance experience with technology and digital health companies. He is also member of the Risk Committee of SHG.
Dr Kwang Guan Tay	Executive Director	Feb 2020	Dr Kwang Guan Tay Executive Director Dr Tay has held various academic positions over the past 20 years (primarily in an adjunct or visiting capacity) at the University of Western Australia, as well as Edith Cowan University. Guan has knowledge in the medical and educational sectors. He is currently an Adjunct Associate Professor at the Faculty of Health and Medical Sciences at the University of Western Australia. Dr Tay has also managed projects at Khalifa University, the premier research-intensive university in Abu Dhabi, the United Arab Emirates.
Mr Denning Sang-Tatt Chong	Founder,Non-Executive Director	Feb 2020	Mr Denning Sang-Tatt Chong Founder,Non-Executive Director Mr Chong has been the principal of James Chong Lawyers since 2004. Denning has had worked across a range of the community - from ASX listed companies and cross border type transactions, to local communities. Denning holds directorships with various property development companies, including currently being a director of the Australian subsidiaries of a SGX listed property developer, with a property portfolio. He is also a director of a boutique venture capital business focusing on property, financial and medical technology sectors. He is also member of the Risk Committee of SHG.
Mr Thomas Sylvanus Hanly	Chief Executive Officer,Managing Director	Feb 2020	Mr Thomas Sylvanus Hanly Chief Executive Officer,Managing Director Mr Hanly in his early career has worked as an economic analyst for AgricultureNZ, before moving to the United States where he obtained his Series 7 and was employed in private banking with Merrill Lynch. With an understanding of capital markets and an interest in technology, he was involved in the early 2000's driving the development and commercialization of a financial services start-up in the United States before returning to Australia. Prior to joining Singular Health, Thomas has held a number of board positions of privately held companies in Australia and Singapore and has acted as an independent consultant assisting with the funding and commercialization of innovative technologies. Recently, Thomas provided strategic technology transfer advice for the development of new acid leach membrane technology from Monash University and helped to develop carbon tax offset strategies with Calibre Group in Perth.
Mr Steven Wood	Company Secretary	N/A

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Howard Digby	27/01/2021	50,000	35,000	1,000,000	N/A
Andrew Just	27/01/2021	N/A	N/A	1,000,000	N/A
Thomas Hanly	20/02/2020	1	3,500,000	6,000,000	N/A
Denning Chong	20/02/2020	N/A	4,380,000	4,500,000	N/A
Kwang Tay	20/02/2020	157,398	N/A	3,000,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Sim Tek Tan	8,780,000	8.59%
Chong Ling Diamond Cheong	7,065,754	6.91%
CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C)	6,280,000	6.14%
JLI Enterprises Pty Ltd (JLI A/C)	4,900,000	4.79%
JCC Health Pty Ltd (The Jde Medvr A/C)	4,380,000	4.28%
Pak Lim Kong	4,073,973	3.99%
Sylvan Capital Pte Ltd	3,500,000	3.42%
SC Consultant Pty Ltd	3,161,918	3.09%
Garry Tet Kheng Chong	3,000,000	2.93%
Wang (Aust) Pty Ltd	2,840,000	2.78%
Peninsula Treescape Pty Ltd	2,700,000	2.64%
Fayweng Pty Ltd	2,000,000	1.96%
Design House (Wa) Pty Ltd	2,000,000	1.96%
Stained Glass Windows Pty Ltd	2,000,000	1.96%
Sandhurst Trustees Ltd (Cyan C3G Fund A/C)	2,000,000	1.96%
Mr Philip John Cawood	1,804,795	1.77%
Richard Tai Pty Ltd	1,500,000	1.47%
Jebtai Pty Ltd	1,500,000	1.47%
Ausglobal One Pty Ltd	1,053,974	1.03%
Dong Chang	1,050,959	1.03%
Grange Consulting Group Pty Ltd	1,000,000	0.98%
Pac Asset Management Pty Ltd	996,850	0.98%
National Nominees Limited	925,000	0.90%
Lombardi Super Pty Ltd	850,000	0.83%
Royanna Pty Ltd	850,000	0.83%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
No Financial Year End data available

SHG Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.